What is Science?
Science Corporation operates as a specialized clinical-stage medical technology enterprise dedicated to the advancement of neural interface and neuro-engineering solutions. The firm focuses on the intersection of biology and technology, developing sophisticated biohybrid devices designed to address severe neurological conditions. By leveraging a vertically integrated model that encompasses research, development, and clinical application, Science Corporation aims to bridge the gap between theoretical neuroscience and practical, life-altering medical interventions. Its core competencies lie in the creation of hardware and software architectures that interface directly with the human nervous system to improve health outcomes, positioning the company as a key player in the burgeoning field of human-machine integration.
How much funding has Science raised?
Science has raised a total of $230M across 1 funding round:
Series C
$230M
Series C (2026): $230M with participation from Lightspeed Venture Partners, Khosla Ventures, Y Combinator, In-Q-Tel, and Quiet Capital
Key Investors in Science
Lightspeed Venture Partners
A global multistage venture capital firm that invests in early and growth-stage technology companies across sectors such as enterprise software, fintech, and infrastructure.
Khosla Ventures
A venture firm providing strategic advice and capital to entrepreneurs working on breakthrough technologies, with a strong focus on health, AI, and sustainable energy.
Y Combinator
A prominent startup accelerator and investment firm that provides seed funding and mentorship to early-stage businesses across various high-growth industries.
What's next for Science?
With the successful closure of this major enterprise-level funding round, Science Corporation is poised to enter a critical phase of operational scaling and clinical validation. The strategic roadmap likely involves the expansion of its internal research capabilities and the intensification of its regulatory engagement to move its neuro-engineering solutions closer to commercial viability. Investors are closely monitoring the firm's progress in human trials, as the successful deployment of its neural interface technology could redefine the standard of care for patients suffering from degenerative neurological disorders. Moving forward, the company will likely focus on optimizing its manufacturing processes and strengthening its intellectual property portfolio to maintain its competitive advantage in the high-stakes medical technology sector.
See full Science company page
